Lipocine (LPCN) EBT Margin (2018 - 2025)

Lipocine's (LPCN) quarterly EBT Margin came in at 2781.46% in Q3 2025, down 685.43% on a QoQ basis from 354.13% in Q2 2025.

Lipocine (LPCN) EBT Margin (2018 - 2025) Analysis & Trends

Lipocine (LPCN) has 7 years of EBT Margin data on file, last reported at 2781.46% in Q3 2025.

Quarterly EBT Margin changed N/A year-over-year to 2781.46% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 126.66% (down 7253.0% YoY) and the FY2024 annual result came in at 0.08%, up 57365.0% from the prior year.
EBT Margin fell to 2781.46% in Q3 2025, from 354.13% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 1055.42% in Q4 2023 to a low of 7037.7% in Q1 2023.
A 5-year average of 1724.68% and a median of 440.24% in 2022 frame the typical range for EBT Margin.
Annual changes were most pronounced in 2024 — EBT Margin soared 708383 bps — and 2025, when it tumbled 203270 bps.
Tracing LPCN's EBT Margin over 5 years: stood at 78.48% in 2021, then slumped by 771 bps to 526.36% in 2022, then soared by 301 bps to 1055.42% in 2023, then slumped by 95 bps to 51.04% in 2024, then slumped by 5549 bps to 2781.46% in 2025.
The last three EBT Margin figures came in at 2781.46% (Q3 2025), 354.13% (Q2 2025), and 1986.57% (Q1 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Lipocine	11.34 Mn	-12.57 Mn	-	-

Download Data